Controlled evaluation of the antitussive activity of viminol p-hydroxybenzoate.
A double-blind cross-over trial was carried out to evaluate the antitussive activity of viminol p-hydroxybenzoate; the comparison was done with three preparations: a placebo and the drug at two doses, 70 and 140 mg respectively. The responses were scored hourly up to 4 hours after the administration of single doses in the morning to subjects with persistent cough. The highest dose of viminol showed a definite antitussive activity, whereas the lowest did not differ from the placebo. The antitussive effect appears clinically useful for the treatment of cough, but further studies are indicated to define optimal dosage schedules.
D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy*; D004983:Ethanolamines / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D062385:Hydroxybenzoates / Q000627:therapeutic use; D008297:Male
D004983:Ethanolamines; D062385:Hydroxybenzoates